Overview

Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).

Phase:

Phase 4

Details

Lead Sponsor:

The University of Hong Kong

Treatments:

Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate